CYP17A1 inhibitor

CYP17A1 inhibitor

CYP17A1 inhibitors are a class of drugs that inhibit the enzyme Cytochrome P450 17A1 (CYP17A1). This enzyme is crucial in the biosynthesis of androgens and glucocorticoids, which are essential for the production of testosterone and other sex hormones. By inhibiting CYP17A1, these drugs can reduce the production of androgens, which is particularly useful in the treatment of hormone-sensitive cancers such as prostate cancer.

Mechanism of Action

CYP17A1 inhibitors work by blocking the activity of the CYP17A1 enzyme, which is involved in two key reactions in the steroidogenesis pathway: the 17α-hydroxylation of pregnenolone and progesterone, and the subsequent 17,20-lyase reaction. This inhibition leads to a decrease in the synthesis of androgens and glucocorticoids, thereby reducing the levels of testosterone and other sex hormones.

Clinical Uses

CYP17A1 inhibitors are primarily used in the treatment of prostate cancer, particularly in cases where the cancer is resistant to other forms of hormone therapy. By reducing androgen levels, these drugs can slow the growth of androgen-dependent cancer cells.

Examples of CYP17A1 Inhibitors

• Abiraterone: A widely used CYP17A1 inhibitor that is often prescribed in combination with prednisone to treat metastatic castration-resistant prostate cancer.
• Ketoconazole: An antifungal medication that also has CYP17A1 inhibitory properties, though it is less commonly used for this purpose due to its side effects.

Side Effects

The inhibition of CYP17A1 can lead to a decrease in the production of glucocorticoids, which may result in side effects such as hypertension, hypokalemia, and adrenal insufficiency. Patients undergoing treatment with CYP17A1 inhibitors are often given corticosteroids to mitigate these side effects.

Research and Development

Ongoing research is focused on developing new CYP17A1 inhibitors with improved efficacy and reduced side effects. Studies are also exploring the potential use of these inhibitors in the treatment of other hormone-sensitive cancers, such as breast cancer.

See Also

• Cytochrome P450
• Steroidogenesis
• Androgen deprivation therapy
• Hormone therapy (oncology)